Q4 2025 · 13F-HR
Tri Locum Partners LPholdings as filed
Filed 2026-02-17 · accession 0001826434-26-000002
$770.1M
Reported value
15
Positions
2025-12-31
Period end
The Brief · Tri Locum Partners LP · Q4 2025
AI · grounded in 13F
Tri Locum Partners LP established a new position in JNJ valued at $124.8M. The fund also initiated new stakes in DHR for $79.4M and LLY for $68M. Additional new positions include UNITED THERAPEUTICS CORP DEL at $58.9M and ASCENDIS PHARMA A/S at $56.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 478160104 | JNJ | JOHNSON & JOHNSON | $124.8M | 16.2% | 603,143 | Common | SOLE |
| 235851102 | DHR | DANAHER CORPORATION | $79.4M | 10.3% | 346,875 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $68.0M | 8.83% | 63,284 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $58.9M | 7.65% | 120,921 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $56.5M | 7.34% | 265,015 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $50.1M | 6.50% | 86,023 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $49.6M | 6.44% | 520,508 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $44.8M | 5.82% | 1,435,865 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $44.1M | 5.72% | 557,174 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $40.8M | 5.30% | 805,689 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $36.8M | 4.78% | 201,627 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $31.7M | 4.11% | 37,653 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $30.9M | 4.01% | 307,371 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $28.0M | 3.63% | 421,600 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $25.6M | 3.33% | 622,403 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.